Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Their PAST filings and (largely foreign) releases/communications revealed that important business plans would come to fruition in December 2020. Multi-year, multi-million dollar government grants and other similar funding streams depend on/correlate with those earlier referenced stages of development. I’m just bummed that I never got around to buying those additional 20M shares for $2,000 late last year when the PPS was still at .0001 (too much going on with work, school, family, holidays, remodel, it being a pain to visit the bank to wire money to my TDA account, etc)—bottom line is I was committed to buying in anticipation of these events, but didn’t make it enough of a priority: failing to do so cost me the eventual opportunity to make over $600,000...
They are not REQUIRED to file updates—they submitted necessary paperwork to “go dark”: what part of this is so hard for people to understand?
The SEC should focus its energy on something with a real purpose. As far as the crooks on WS go, SERIOUS, COMPREHENSIVE reform is needed. Recent changes in law making it ILLEGAL to short nakedly must now be followed with simple enough but COMPREHENSIVE data systems to validate that each “market maker” (MM) is ONLY selling/buying shares he/she ACTUALLY HAS—and that exchanges BETWEEN MMs are accounted within this equation in the same manner as well. All of these steps would remove most of the shadiness and guesswork that currently encrust most transactions of stocks—particularly in the OTC. TRANSPARENCY ALONE will allow folks to know a truer sense of appropriate valuation of a given share of stock. There is no reason WHATSOEVER that we cannot, using EXISTING technology, map EVERY SINGLE SHARE traded to a legitimately existing share—in real time. This would be a huge advance and MUST be done ASAP. The “democratizing” effect would be profound...
The math is this: they’ve had 3 years to show financial results of “commercialization” (THEIR word) with CaverStem—and it has failed worse than a cheap firecracker on the 4th of July.
Bingo: WHERE’S THE BEEF?! So far, after 2 full YEARS of “commercialization” of CaverStem, LAUGHABLE financial from a company that had a “contract with Russia contract,” promoted Dr. G. to head CaverStem International (as a separate legal entity), and hired supposed marketing guru Gary Mells and whoever that female marketer was that had previously worked for Dr. G.’s clinic (I can’t recall her name). ALL of this activity was aimed at promoting CaverStem. Two years is PLENTY of time to see impact: WHERE ARE THE DRAMATIC FINANCIAL RESULTS? Hint: there are none (and none are forthcoming). Meantime during the last 3 years we’ve seen a run up to .07, followed by a crash down all the way to .0002 and a 1:150 R/S—which was announced during the SAME WEEK in October 2019 when Tim and Don declared that they “had delivered,” were “rewarding” our patience, and “protecting shareholder value.” SINCE the RS we’ve seen the OS balloon (again) from under 50M to over ONE BILLION—IN ONE YEAR. Now we see the creation of a NEW category of restricted shares that would be unaffected by any FUTURE R/S. You do the math here...
I was sucked in by the weight that I gave to social media posts of prominent medical professionals (why would they associate with anything other than a solid firm—and then promote it publicly, I thought to myself?). I also took the PRs (1) at face value and (2) as representing part of a coherent BUSINESS PLAN (which we STILL haven’t seen—and I’ve been here 3 years). This truly is mind-boggling to anyone who seeks a comprehensive, rational approach to analysis and assessment...
Expect ZERO clarity from the management about anything that a business analyst would want to know about a company in order to make reasoned predictions about present/future valuation. The are unwilling (or unable) to communicate this sort of information—at least over the course of the 3 years that I’ve seen. Is it any wonder, then, that we’ve seen what we have with the OS, the PPS, and LAUGHABLE revenues from a company that has been in the “commercialization” stage with its first line, CaverStem, for over two years (reaching back FAR before the pandemic)?
+1. For 3 years the market has agreed with you...
How did those Tweets by Drs. G and S turn out 3 years ago? Same leopards, same spots...
Welcome to CELZ! Lucy is played here by Tim and Don, Charlie by us long INVESTORS (not penny flippers), and the football is CaverStem. Funny how they seem to have forgotten that one—are we supposed to give them a mulligan for that COLOSSAL business failure (which they pumped, even though the business was unwilling or unable to execute a plan aimed at marketing CaverStem to the point of corporate profitability—or even fiscal stability)? And just what IS your “area of core concentration,” Tim? Does CaverStem fall inside or outside that scope? Inquiring minds want to know...
Since when are BUSINESSES not responsible for the clear articulation and timely execution of THEIR business plans and strategies? Lmao
Unfortunately this isn’t a game of golf among friends—there are no mulligans, no “do overs” on colossal mistakes. Newbies—and veterans—deserve clear explanations about what happened with CaverStem when PRINCIPALS were chirping on social media about the effectiveness of the procedure 3 years ago—despite the company’s inability/unwillingness to capitalize on the scenario suggested at that time.
I’m in the same shape. To be clear: I am mainly angry that PRINCIPALS created an impression on social media 3 years ago that did not align with the plans (or abilities) of the company to execute. Best case=ineptitude, worst=malfeasance. This is a VERY fair discussion to have...
“Changing lives” typically means returns in the millions. Those of us who “were patient” for 3 years and had our haul hacked by a factor of 150 have indeed had our lives changed—but not in the positive manner that you suggested...
I appreciate your kind words. Too rare in this “gotcha-minded”, ego-driven world.
I don’t: I HEAR unanswered questions. While I’m happy for the gains of the last months, I’m still down 90%—and won’t quit until we get clarity, or they shut their doors.
Good to see another familiar face back at the scene of the crime that we all witnessed. Again, I ask anyone who claims to “know about this company: what specifically is different NOW that they couldn’t do 3 years ago (let’s not forget that, as an alternative therapeutics company, they benefitted from “Right to Try” legislation a couple years back—what RESULTS directly relatable to PPS did they “deliver” to shareholders, as they claimed in October 2019, now that we are approaching 1.5 years AFTER that declaration?). And more basically, what are the specific revenue streams and activity channels that make up the BUSINESS PLAN? None of their PRs has ever addressed these fundamental business questions. Therefore I remain skeptical (hopeful but skeptical—since HOPE is not a STRATEGY, in business or anywhere else in life).
Looks parabolic—or close to it—to me!
Good for you: unlike those who sank large coin into this same company believing that this would happen 3 years ago—only to get scorched and crushed by a 1:150 R/S caused largely by the company’s unwillingness and/or inability to unfurl the very factors that we now believe will drive this skyward—you benefit from a fortunate timing. I too will become wealthy, if this continues up, but it has a LONG way to go before I could consider overlooking what is written above.
I won’t even THINK to consider ANY of this as truly significant until this hits $5/share. Until then I will divide whatever PPS is current by 150. Today’s close: .000536
I have always believed in the underlying stem cell technology’s potential, but what elements UNIQUE TO THIS COMPANY exist to drive dramatically increased market cap, and how are these features any less present than they were, say, two years ago? For example, there is nothing meaningfully different about CaverStem—which alone of all the CELZ product lines had the potential to take a substantial chunk out of the established market shares of current ED treatments in a way that, if this scenario is realistic, should already have sent this stock to dollars (particularly when the PPS was .03 and the OS under 50M shares exactly one year ago)? I have yet to read any clear answers to the compelling business questions—including from the company itself...
I’ve yet to see THAT: “we delivered” a 1:150 R/S. Divide current PPS by 150=.00021
AND the OS swelled from under 50 THOUSAND shares one year ago at time of R/S to over one BILLION today. Are THOSE the promises you’re referring to?
PS: I will NEVER go away completely, and will ALWAYS tell the truth of what we have experienced here over the last 3 years
Sad how so many said the SAME THINGS 3 YEARS ago, believing what you believe—and we got ROASTED. I’m here at the scene of the crime to add a little counterbalance, to prevent any more innocent victims. The market knows ALL: if/when it’s justified, stocks climb and don’t tank backward 99%...
I remember a time when “FDA approval wasn’t required” because CaverStem isn’t a drug. Somehow SOME have lost sight of that fact—and of its logical corollaries...
While I like the idea of gaining some of my money back (I’ve held long for 3 years believing this was an investment, not a “play”), how precisely are the characteristics that your friends attribute to the company any different than what was known (or reasonably surmised) years ago?
Some of us said the same things about CaverStem 3 YEARS ago, yet here we sit after a crash from .07 to .0002 and a 1:150 reverse split. And to be clear ALL of these trends were established LONG before COVID...
Wouldn’t anyone potentially interested in buying them out have done so when the PPS was somewhere close to .0002 (after all, CELZ has had essentially the same business focus, leadership etc. for at least the past 3 years—so the desirability, IF PRESENT, would have been clear even then when the PPS was in the trips? When you buy someone out, you buy out their OS at a given PPS: why would someone be interested in paying dramatically more for a company they could have gotten for .0002 just 1 year ago? This pipe dream you’re purveying is all emotion, no logic.
One precondition (that any intelligent investor should demand): provide a CLEAR BUSINESS PLAN that lays out specific revenue streams, their anticipated depth and interrelation, and action timelines. As of this very moment—as has been true for the last 3 years—CELZ’ “revenues” (despite the fact that they have been in “commercialization” of CaverStem, their only product line that is past the clinical stage for 2 YEARS) comes from a syringe kit that they PURCHASE and then make something like $1,500 per instance on with each use by the doctor based on their “exclusive distribution rights” within the urology space. However, as Tim reminded us in an October 2019 just days before the R/S was announced, they don’t believe in charging the doctors royalties for the right to use their “patented procedures.” So again, the question remains unanswered: where will revenues come from that will be sufficient to drive the PPS up given an OS that has swelled from under 50 THOUSAND one year ago to 3/4 BILLION today? Until they answer these BASIC BUSINESS QUESTIONS, I will continue to regard them as the same leopards with the same spots...
Lol. Whatever PPS they achieve is divisible by 150. Not sure what they will do differently now to cause the market to see value that they didn’t couldn’t do at any time over the last 3 years. Keep in mind too that the OS was under 50 THOUSAND shares one year ago at the R/S—now we are at 3/4’of a BILLION...
The only folks who need luck are those invest their hard-earned money believing that Tim and Don are gonna grow it.
Yep—and I saw all the news releases that flamed out over the last 3 years. More perspective: after 1 year following the R/S (to mention nothing of all the disasters the preceded—and precipitated it) we are currently 13.7% BELOW the PPS in effect after the R/S.
And as for your claim that my thinking is “negative” (the implication being that it is UNJUSTLY so), feel free to DISPROVE any of my claims with objective, factual figures and evidence: I always look forward to the chance to sharpen already strong arguments...
Wrong. I mean every word I’ve written—including my unwillingness to give this bunch another red cent of my money. Just waiting for karma—and I’ll be watching when she arrives...
That’s total BS: the bottom was falling out with CaverStem LONG before COVID developed into a full-scale problem in the US near the END of Q1 2020. Go back and look at the absurdly low revenues generated by the company for all of 2018 and especially 2019, when “commercialization” was supposedly taking place. Moreover, with principals, including Dr. G. touting the efficacy of CaverStem repeatedly on social media in early and mid 2018, a huge amount of attention (and money) came here, the result of which drove the PPS from around .018 (where I got in roughly) up to .07–only to crash down all the way to .0002 and a 1:150 R/S. In what weird universe is this “protecting shareholder value”? Trust me, I know plenty about CELZ—much that many here (who are mostly newbies) probably haven’t even heard of. Since these all failed to materialize in an adequately visible way that would support and increase the PPS (the only really meaningful measure of a public company’s success), the leaders should be held to account for these failures: Russia contract, cachexia indications, woefully anemic growth of CaverStem despite the hiring of Gary Mells and whoever that female marketer was that had previously worked for Dr. G.’s clinic (I can’t recall her name). I could go on, but that’s a good start...
They have been “commercializing” CaverStem for over two YEARS—and are still pulling in paltry THOUSANDS in revenues per QUARTER. The numbers are in black and white in the filings. It is also known that they do not charge royalties to physicians for the right to perform CaverStem, a philosophical perspective reiterated by Tom in an October 2019 podcast a mere day or two before the “we delivered” PR—and the announcement of the 1:150 R/S. So, again, I ask: WHERE’S THE BEEF? Where are revenues going to come from that are sufficient to drive the PPS up? Why have they been fumbling and flopping around for 3 years with this pipe dream of commercialization: I’ve seen enough over this period to know that this bunch couldn’t market ice water in He!! Now it should be clear why we STILL have provided no business plan—they have none. They delivered alright...
The same (few) doctors who got onboard with CaverStem? That has turned out to be a total joke and floo commercially. Where’s the beef?
If that were true, the market would have already sensed it (probably 2 or 3 years ago) and taken this up to dollars—not down to .0002. Anyone who really matters knows what CELZ is doing and what they can do in the future. Fact: search something like “stem cell biggest players”—and tell me how far down you have to dig in order to find mention of CELZ—if you do even find them...